Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 Molecular Imaging of Sarcoma and Normal Tissues: A Mouse-Human Phase I Co-Clinical Trial 1 Melodi Javid Whitley CTOS 2014 Berlin, Germany.

Published byRoderick Jackson Modified over 9 years ago

Similar presentations

Presentation on theme: "1 Molecular Imaging of Sarcoma and Normal Tissues: A Mouse-Human Phase I Co-Clinical Trial 1 Melodi Javid Whitley CTOS 2014 Berlin, Germany."— Presentation transcript:

1 1 Molecular Imaging of Sarcoma and Normal Tissues: A Mouse-Human Phase I Co-Clinical Trial 1 Melodi Javid Whitley CTOS 2014 Berlin, Germany

2 All Rights Reserved, Duke Medicine 2011 Disclosure Patent for imaging device Lumicell Inc. –Scientific Advisory Board –Stock –Small Business Innovation Research (SBIR) Grant from the NCI, NSF

3 All Rights Reserved, Duke Medicine 2011 Proposed Solution A system for optical intra-operative detection of microscopic residual disease within the tumor bed Clinical Problem After limb-sparing surgery alone, 1/3 of STS will recur locally Method 1.Molecularly label tumor cells with a fluorescent agent 2.Detect residual fluorescence using a handheld imaging device

4 All Rights Reserved, Duke Medicine 2011 Targeting Cathepsin Proteases in Cancer 4 SarcomasMuscle (Mito JK, et al. Cancer 2012)(Cuneo KC, Mito JK, Whitley MJ et al. Cancer 2012)

5 All Rights Reserved, Duke Medicine 2011 LUM015: A Cathepsin-Activatable Fluorescent Probe 5 CTS

6 All Rights Reserved, Duke Medicine 2011 LUM015: A Cathepsin-Activatable Fluorescent Probe 6

7 All Rights Reserved, Duke Medicine 2011 Tumor Specificity 77 (Mito JK, et al. Cancer 2012) Tumor Muscle

8 All Rights Reserved, Duke Medicine 2011 A Phase I Study of the Safety and Activation of a Cathepsin- Activatable Fluorescent Cancer-Specific Probe LUM015 88 Primary Objective To determine a safe and recommended phase II dose of LUM015 that labels tumors in human patients. 15 patients enrolled (12 STS, 3 Breast Cancer) IV LUM015 @ 0.5-1.5 mg/kg No Adverse Pharmacological Activity (APA)

9 All Rights Reserved, Duke Medicine 2011 A Phase I Study of the Safety and Activation of a Cathepsin- Activatable Fluorescent Cancer-Specific Probe LUM015 99 Primary Objective To determine a safe and recommended phase II dose of LUM015 that labels tumors in human patients Secondary Objectives 1)To image tumor and normal tissue 2)To obtain PK/PD information 3)To analyze cathepsin protease expression in tumors

10 All Rights Reserved, Duke Medicine 2011 Study Design 10 Safety Evaluations Safety Evaluations + PK Studies

11 All Rights Reserved, Duke Medicine 2011 Tissue Fluorescence 30 Hours After IV LUM015 11 Cohort 2a 3 @ 1.0 mg/kg LUM015 Image @ 30 hours Cohort 1 3 @ 0.5 mg/kg LUM015 Image @ 30 hours Human

12 All Rights Reserved, Duke Medicine 2011 Human and Mouse LUM015 Plasma Pharmacokinetic Profiles are Nearly Identical 12

13 All Rights Reserved, Duke Medicine 2011 Tissue Fluorescence 6 vs 30 Hours After IV LUM015 13 Cohort 2a 3 @ 1.0 mg/kg LUM015 Image @ 30 hours Cohort 1a 3 @ 0.5 mg/kg LUM015 Image @ 30 hours Cohort 3 3 @ 1.5 mg/kg LUM015 Image @ 6 hours Cohort 2b 3 @ 1.0 mg/kg LUM015 Image @ 6 hours Cohort 1b 3 @ 0.5 mg/kg LUM015 Image @ 6 hours Human

14 All Rights Reserved, Duke Medicine 2011 Tumor Fluorescence is Significantly Higher than Normal Tissue Fluorescence 14

15 All Rights Reserved, Duke Medicine 2011 Tumor: Normal Fluorescence Ratios are Independent of Dose 15

16 All Rights Reserved, Duke Medicine 2011 In Summary 12 STS, 3 Breast Cancer patients received LUM015 without APA Co-clinical studies identified an optimal imaging time of 6 hours after LUM015 injection Human tumor-specific fluorescence can be detected with the LUM imaging device Tumor-to-normal contrast is dose-independent within the tested dose range 0.5 mg/kg LUM015 will be used in further clinical studies 16

17 All Rights Reserved, Duke Medicine 2011 Acknowledgements Kirsch Lab David Kirsch, MD, PhD Jeff Mito, MD, PhD Kyle Cuneo, MD Nerissa Williams Yan Ma MIT Moungi Bawendi, PhD Linda Griffith, PhD Lumicell Inc. Jorge Ferrer, PhD David Strasfeld, PhD David Lee, MS Duke MSTP Clinical research team Brian Brigman, MD Diana Cardona, MD Joan Cahill, RSCN, RGN, OCN Erin O’Reilly, PhD Alex Lazarides, BSc Dan Blazer, MD Will Eward, MD Douglas Tyler, MD Shelley Hwang, MD, MPH Rachel A. Greenup, MD, MPH Paul Mosca, MD, PhD Nicole Larrier, MD Richard Riedel, MD DCI PK/PD Core Laboratory Ivan Spasojevic, PhD 17

18 18

19 All Rights Reserved, Duke Medicine 2011 Phase I Case Study 19

20 All Rights Reserved, Duke Medicine 2011 Patient #2: 38 year old female with core biopsy proven pleomorphic undifferentiated high-grade sarcoma s/p neoadjuvant radiation therapy 20

21 All Rights Reserved, Duke Medicine 2011 Patient #2 21 Potentially viable tumor Grossly necrotic tumor Muscle Skin

22 All Rights Reserved, Duke Medicine 2011 Patient #2 TEXT 22 Viable Tumor Necrosis Myxoid Tumor

23 All Rights Reserved, Duke Medicine 2011 Patient #2 23 Skin Muscle

24 All Rights Reserved, Duke Medicine 2011 Patient #2 24

25 All Rights Reserved, Duke Medicine 2011 TITLE TEXT 25

26 All Rights Reserved, Duke Medicine 2011 PHASE I TABLE TEXT 26

27 All Rights Reserved, Duke Medicine 2011 Can Residual Fluorescence Predict Local Recurrence? 27 CRE Lum015 TumorTumor Bed (+) Residual Fluorescence Tumor Bed (-) Residual -Fluorescence Follow for Local Recurrence Braf Ca ; p53 fl/fl

28 All Rights Reserved, Duke Medicine 2011 28 Increase Dose: 3 @ Dose Level 2 Dose Level 3 is established as a safe dose for future phase II studies 3 @ Dose Level 1 Decrease Dose: 3 @ Dose Level -1 Trial stops w/o safe dose for future phase II studies Dose Expansion: 3@ Dose Level -1 Trial stops w/o safe dose for future phase II studies Dose Level -1 is established as a safe dose for future phase II studies Increase Dose: 3 @ Dose Level 3 Dose Expansion: 3 @ Dose Level 3 Decrease Dose: 3@ Dose Level 1 Decrease Dose: 3@ Dose Level 2 Dose Level 2 is established as a safe dose for future phase II studies ≥1 subjects with adverse pharmacologic activity No subjects with adverse pharmacological activity START HERE

29 All Rights Reserved, Duke Medicine 2011 Dose Escalation 29 Dose LevelLUM015 (mg/kg) 0.25 10.50 21.0 31.5 3/3 2/3 No Adverse Pharmacological Events

Download ppt "1 Molecular Imaging of Sarcoma and Normal Tissues: A Mouse-Human Phase I Co-Clinical Trial 1 Melodi Javid Whitley CTOS 2014 Berlin, Germany."

Similar presentations

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.

Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Brown JR et al. Proc ASH 2013;Abstract 523.

Brown JR et al. Proc ASH 2013;Abstract 523.
1 Preliminary Analysis Of Phase I, First- In-Human, Cathepsin Activated Tumor Imaging Probe Brian Brigman November 1, 2013 1.

1 Preliminary Analysis Of Phase I, First- In-Human, Cathepsin Activated Tumor Imaging Probe Brian Brigman November 1,
Could fasting while receiving chemotherapy be beneficial?

Could fasting while receiving chemotherapy be beneficial?
Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI

Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI
Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
SARC023 Phase I/II trial of ganetespib, an heat shock protein 90 inhibitor in combination with the mTOR inhibitor sirolimus for patients with unresectable.

SARC023 Phase I/II trial of ganetespib, an heat shock protein 90 inhibitor in combination with the mTOR inhibitor sirolimus for patients with unresectable.
Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection For Subcutaneous, Intraperitoneal, Intravenous and Oral Use For Diagnostic Use by.

Kit for the Preparation of Technetium Tc 99m Sulfur Colloid Injection For Subcutaneous, Intraperitoneal, Intravenous and Oral Use For Diagnostic Use by.
Title, in bold style Subtitle, in regular Max 3 lines of text totally NB! The graphic outside the slide will not show in “Slide Show” or on print WntResearch.

Title, in bold style Subtitle, in regular Max 3 lines of text totally NB! The graphic outside the slide will not show in “Slide Show” or on print WntResearch.
Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.

Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.
Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.

Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.

Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
NMF 3/6/03 Susan Galbraith, MB BChir PhD Vice President Clinical Discovery Oncology & Immunology Phase 0 Trials Why aren’t they more widely used by industry?

NMF 3/6/03 Susan Galbraith, MB BChir PhD Vice President Clinical Discovery Oncology & Immunology Phase 0 Trials Why aren’t they more widely used by industry?
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.

Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
CS-1 Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer William J. Gradishar, MD, FACP Professor of Medicine Northwestern.

CS-1 Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer William J. Gradishar, MD, FACP Professor of Medicine Northwestern.
Clinical Case Nº3 Dr. Markus Schuler. Case description 58-year-old man History of severe cardiac problems Large tumour in the left thigh Tests results:

Clinical Case Nº3 Dr. Markus Schuler. Case description 58-year-old man History of severe cardiac problems Large tumour in the left thigh Tests results:

Similar presentations

Ads by Google